What is the modern evolution of high-dose methotrexate therapy, including dosing, hydration, urine alkalinization, leucovorin rescue, and glucarpidase use?

High-Dose Methotrexate Evolution: Modern Protocol

Modern high-dose methotrexate (HDMTX) therapy has evolved into a standardized protocol requiring aggressive hydration (3 L/m²/day), urine alkalinization to pH >7.0, leucovorin rescue starting 24 hours post-infusion at 15 mg every 6 hours for 10 doses, and glucarpidase for severe delayed elimination or acute kidney injury, with fixed 2000-unit dosing now replacing weight-based strategies.

Dosing Standards

HDMTX is defined as doses >500 mg/m², with contemporary protocols typically using:

• 3-3.5 g/m² for CNS prophylaxis in lymphoma 1
• 12-15 g/m² for other malignancies 2, 3
• Administered as IV infusion over 4 hours 3

The median regimen involves 2 cycles for CNS prophylaxis, with 81% of patients receiving ≥3 g/m² 1. Dose reductions occur in 14-26% of patients due to renal toxicity or delayed clearance 1.

Hydration Protocol

The FDA-mandated hydration strategy remains the cornerstone 2:

• Pre-hydration: 1,000 mL/m² IV over 6 hours before methotrexate infusion
• During and post-infusion: 125 mL/m²/hr (3 L/m²/day) continuing for 2 days after completion
• This aggressive approach prevents methotrexate crystallization in renal tubules, the primary mechanism of nephrotoxicity 4

Urine Alkalinization

Maintain urine pH >7.0 throughout methotrexate infusion and leucovorin therapy 2, 3. This is accomplished by:

• Oral sodium bicarbonate, OR
• IV sodium bicarbonate incorporated into hydration fluids

Alkalinization increases methotrexate solubility and prevents tubular precipitation 5, 4.

Leucovorin Rescue Evolution

Standard Protocol

Begin leucovorin 15 mg (approximately 10 mg/m²) every 6 hours starting exactly 24 hours after methotrexate infusion begins 3. Administer for 10 doses (60 hours total) 3.

Pharmacokinetically-Guided Adjustments

The protocol has evolved to include MTX level-based dose escalation 3, 5:

Normal elimination (MTX ~10 µM at 24h, ~1 µM at 48h, <0.2 µM at 72h):

• Continue standard 15 mg every 6 hours

Delayed late elimination (MTX >0.2 µM at 72h, >0.05 µM at 96h):

• Continue 15 mg every 6 hours until MTX <0.05 µM

Delayed early elimination or AKI (MTX ≥50 µM at 24h OR ≥5 µM at 48h OR creatinine doubles):

• Escalate to 150 mg IV every 3 hours until MTX <1 µM
• Then 15 mg IV every 3 hours until MTX <0.05 µM 3

Critical Caveat

Never administer leucovorin intrathecally 2, 3. Recent evidence suggests leucovorin does not interfere with glucarpidase efficacy and can be continued concurrently 6, challenging older recommendations to pause leucovorin around glucarpidase administration.

Glucarpidase: The Modern Evolution

Indications

Glucarpidase is indicated for severe delayed elimination or AKI 7, 5, 4:

• MTX ≥50 µM at 24 hours
• MTX ≥5 µM at 48 hours
• Creatinine increase ≥100% at 24 hours
• Severe toxicity despite leucovorin rescue

Dosing Evolution: Fixed vs. Weight-Based

The most significant recent evolution is the shift from weight-based (50 U/kg) to fixed-dose glucarpidase. A 2026 study demonstrated that fixed 2000-unit dosing achieved:

• Identical time to renal recovery compared to weight-based dosing
• Significantly faster administration (45.1h vs 71.5h post-HDMTX, p=0.015)
• Lower peak creatinine elevation (2.8-fold vs 3.8-fold, p=0.034)
• Trend toward less dialysis requirement and shorter hospital stays 7

Emerging evidence supports even lower doses: 25 U/kg (half-dose) achieved 94.6% MTX reduction in a 2026 case report, offering cost-effective alternatives particularly relevant for adult patients where weight-based dosing substantially increases costs 8.

Timing and Administration

• Administer as soon as severe delayed elimination is identified 5, 4
• Glucarpidase rapidly metabolizes >99% of extracellular methotrexate regardless of concurrent leucovorin 6
• Continue aggressive hydration and alkalinization alongside glucarpidase 3, 4

Important Limitation

Glucarpidase only clears extracellular methotrexate; it does not affect intracellular stores 9, 4. Therefore, leucovorin rescue must continue to provide reduced folate for intracellular rescue.

Monitoring Requirements

Pre-Treatment Screening

Delay methotrexate if 2:

• WBC <1,500/µL or neutrophils <200/µL
• Platelets <75,000/µL
• Bilirubin >1.2 mg/dL or SGPT >450 U
• Creatinine clearance <60 mL/min
• Active mucositis
• Pleural effusion present (drain before infusion)

During Treatment

• Measure serum creatinine and MTX levels at 24 hours post-infusion, then at least daily until MTX <0.05 µM 2, 5
• Monitor urine pH continuously
• Assess for clinical toxicity (mucositis, myelosuppression, hepatotoxicity)

Decision Support Tools

The MTXPK.org web-based tool can predict MTX clearance curves and identify patients requiring glucarpidase, with 100% concordance with published guidelines in validation studies 10. This tool may prevent unnecessary glucarpidase use (38.5% of administrations were potentially unnecessary in one series) 10.

Common Pitfalls

1. Inadequate alkalinization: Failure to maintain pH >7.0 increases crystallization risk
2. Delayed glucarpidase: Waiting too long when severe delayed elimination occurs worsens outcomes 7
3. Drug interactions: NSAIDs, penicillins, and proton pump inhibitors can impair MTX clearance 3, 4
4. Third-space fluid: Pleural effusions act as MTX reservoirs and must be drained pre-treatment 2
5. Stopping leucovorin for glucarpidase: Recent evidence shows this is unnecessary 6

Risk Stratification

High-risk patients requiring intensified monitoring 5, 4:

• Pre-existing renal dysfunction
• Volume depletion
• Acidic urine
• Concurrent nephrotoxic medications
• Third-space fluid accumulation
• Advanced age

These patients warrant more frequent MTX level monitoring and lower thresholds for leucovorin dose escalation or glucarpidase administration.